Medpace Holdings Stock - Analyst consensus and technical picture into late June

Medpace Holdings stock currently trades near recent highs on Nasdaq while analyst consensus signals a hold and modest downside to the average target. On this Thursday, the focus is on how the chart setup lines up with Wall Street expectations.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 17:15 UTC. Details in the imprint.

Medpace Holdings Inc (US5840631062) is trading close to its recent highs on Nasdaq after a strong run in recent months. On this Thursday, the spotlight is on the interplay of chart levels and analyst expectations for the contract research specialist.

What the latest data show

On Thursday, Medpace shares changed hands around the mid-$450 range, with one real-time quote service citing a fair value indication at about $456.37 as of the morning session. Another trading portal showed a last price of roughly $460.63, implying a market capitalization near $13.1 billion.

The slight divergence between data sources reflects different update times and quote providers, but both confirm that the stock is trading not far from its all-time highs reached earlier this year. Trading volumes remain moderate compared with larger healthcare names, consistent with Medpace's mid-cap profile.

Analyst consensus remains cautious

Analyst data compiled by one market platform point to an overall "hold" stance on Medpace, with an average price target near $440.10 per share. That is modestly below current trading levels, signaling limited upside in the consensus view at this point.

The same source lists a price-earnings ratio in the high-20s on a trailing basis, reflecting the strong profit growth Medpace reported in recent quarters. Against this backdrop, some investors may see the valuation as full, while others focus on the company's robust execution in the contract research market.

Chart and technical picture this Thursday

From a technical perspective, Medpace shares have been in a clear long-term uptrend, with the stock trading well above shorter moving averages in recent weeks. The recent consolidation around the mid-$450 region follows a strong advance earlier in the year, leaving the stock at elevated levels on many charts.

Although detailed intraday technical indicators vary by platform, the overall setup suggests that the long-term trend remains intact while short-term swings are driven by broader market sentiment in healthcare and growth stocks. For chart-oriented traders, the key levels to watch are the recent highs and the support zones around prior breakout areas.

The business behind the stock

Medpace generates its revenue as a clinical contract research organization, managing and running clinical trials for biotechnology, pharmaceutical and medical device companies globally. The group offers services spanning study design, site management, data analysis and regulatory support across multiple therapeutic areas.

Where the stock trades today

Medpace Holdings stock (US5840631062) trades on Nasdaq at about $460.63 as of 06/18/2026, 17:00 UTC, based on delayed market data in U.S. dollars.

Medpace Holdings at a glance

• Company: Medpace Holdings Inc
• ISIN: US5840631062
• WKN: A2AHC5
• Ticker: MEDP
• Venue: Nasdaq
• Price (as of 06/18/2026, 17:00 UTC): 460.63 USD
• Market cap: 13,120,000,000 USD (as of 06/18/2026)
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Index membership: Standard & Poor's 400 MidCap index
• Next earnings date: 07/22/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.